Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

P Iversen, C J Tyrrell, A V Kaisary, J B Anderson, L Baert, T Tammela, M Chamberlain, K Carroll, K Gotting-Smith, G R Blackledge

    156 Citationer (Scopus)

    Abstract

    To compare the efficacy, tolerability, and quality of life benefits of bicalutamide (Casodex) 150-mg/day monotherapy and castration in previously untreated nonmetastatic (M0) advanced prostate cancer.
    OriginalsprogEngelsk
    TidsskriftUrology
    Vol/bind51
    Udgave nummer3
    Sider (fra-til)389-96
    Antal sider8
    ISSN0090-4295
    StatusUdgivet - 1998

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years'. Sammen danner de et unikt fingeraftryk.

    Citationsformater